Pathfinder Medical recently announced the appointment of interventional radiologist Lorenzo Patrone (Azienda USL Toscana Centro, Florence, Italy) as its chief medical officer (CMO).
Patrone has been collaborating with Pathfinder since 2019 as lead clinical consultant. A press release states that he has played a pivotal role in the development and validation of the company’s ePath catheter system, which is designed to enable precise, minimally invasive vascular connections.
During his time with Pathfinder, Patrone has performed the first clinical cases using the company’s CE-marked first-generation ePath device to treat lower limb chronic total occlusions (CTOs). He has also led Pathfinder’s preclinical endovascular arteriovenous fistula (endoAVF) studies, including the GLP in-vivo trial, and will now serve as an investigator in the upcoming first-in-human study for wrist-level endoAVF creation.
Sorin Popa, chief executive officer (CEO) of Pathfinder Medical, said: “Lorenzo has been a driving force behind the clinical progress of our technology. His extensive endovascular experience, creativity, and passion for improving patient outcomes make him an exceptional addition to our leadership team as we advance toward commercialisation.”
Pathfinder notes in its press release that Patrone brings over a decade of international experience as a consultant vascular and interventional radiologist, currently at Azienda USL Toscana Centro. He has published widely on endovascular innovation, served as assistant editor for the Journal of Endovascular Therapy, and is active in global vascular education through initiatives such as Vascupedia VIEWS and having founded the FYA Congress.
Patrone commented: “Creating reliable, minimally invasive vascular access has long been one of the holy grails in interventional medicine. Having worked closely with Pathfinder for over six years, I’ve seen the transformative potential of its technology and am excited to help guide its journey from concept to clinical adoption.”
